Prot# MLN0002-3026: A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects with Ulcerative Colitis

Project: Research project

Project Details

StatusFinished
Effective start/end date5/2/175/2/20

Funding

  • Quintiles, Inc. (Prot# MLN0002-3026)
  • Takeda Development Center Americas, Inc. (Prot# MLN0002-3026)